Breast Cancer
Jan 29, 2025, 08:05
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared a post on X:
“Final analysis of the PRECIOUS phase 3 trial out in Journal of Clinical Oncology. Despite yielding only a small PFS advantage, pertuzumab rechallenge in HER2+ MBC led to a relevant OS benefit (Δ 10 mo). Could become actionable if T-DXd/pertuzumab make it to the first line.”
Authors: Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Naruto Taira, Satoshi Morita, Masakazu Toi, Shinji Ohno Norikazu Masuda
cancer
Fumikata Hara
Hiroji Iwata
Kenji Tamura
Koichiro Tsugawa
Masahiro Kashiwaba
Masakazu Toi
Masato Takahashi
Naoki Niikura
Naruto Taira
OncoDaily
Oncology
Paolo Tarantino
Satoshi Morita
Shigehira Saji
Shinji Ohno Norikazu Masuda
Takashi Yamanaka
Takayuki Ueno
Tatsuya Toyama
Tetsuhiro Yoshinami
Tomomi Fujisawa
Toshimi Takano
Yoshie Hasegawa
Yutaka Yamamoto
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 29, 2025, 08:02
Jan 29, 2025, 07:53
Jan 29, 2025, 07:48
Jan 29, 2025, 07:46
Jan 29, 2025, 07:39
Jan 29, 2025, 07:38